Abstract
The genetic classification of DLBCL identified subgroups that benefit from addition of ibrutinib and its underlying mechanism.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1158/2159-8290.cd-rw2021-163
Journal: Cancer Discovery | Publication Date: Jan 1, 2022 |
The genetic classification of DLBCL identified subgroups that benefit from addition of ibrutinib and its underlying mechanism.
Join us for a 30 min session where you can share your feedback and ask us any queries you have